Molecular and functional correction of a deep intronic splicing mutation in <i>CFTR</i> by CRISPR-Cas9 gene editing.

"figures s1-s4 and tables s1-s4 data s1 u3 crispor data s2 d1 crispor data s3 u3 cosmid data s4 d1 cosmid document s2."

"Declaration of interests S.H. has shares in Ryboquin Ltd."

"This research was supported by a Strategic Research Award (SRC 006) from the 10.13039/501100000292Cystic Fibrosis Trust. This work was also supported by the 10.13039/100014461National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and 10.13039/501100000765University College London. Funding for the Harrison laboratory also came from 10.13039/100000897Cystic Fibrosis Foundation grant HARRIS14XX0 and CF Trust grant VIA011. We would like to thank Dr Scott Randell, University of North Carolina, for generous provision of the CFTR 3849+10kb C>T basal cells. Provision of cells by Dr. Randell was supported by grants from the 10.13039/100000897Cystic Fibrosis Foundation (BOUCHE15R0) and the NIH (DK065988)."